Delayed-Onset Nodules Secondary to a Smooth Cohesive 20 mg/mL Hyaluronic Acid Filler

Beleznay, Katie; Carruthers, Jean; Carruthers, Alastair; Mummert, Mark E.; Humphrey, Shannon

doi:10.1097/dss.0000000000000418

Cited by 126 publications

(168 citation statements)

References 9 publications

Supporting

Mentioning

156

Contrasting

Unclassified

Order By: Relevance

“…identified a 0.5% incidence of delayed nodule formation (out of 4702 HA filler treatments performed) with a median time of onset of 4 months. The median time to resolution of these nodules was 6 weeks . It is likely that a low‐grade hypersensitivity to one of the constituents of the filler (protein contaminant, preservative or components of cross‐linking) in predisposed individuals is the cause with or without the need for a trigger such as a systemic infection.…”

Section: Nodule Formation and Granulomatous Reactionsmentioning

confidence: 99%

Dermal fillers: pathophysiology, prevention and treatment of complications

Chiang

Pierone

Al‐Niaimi

2016

Acad Dermatol Venereol

130

141

View full text Add to dashboard Cite

Dermal fillers are increasingly used for soft tissue augmentation of the face and hands. The widespread use of dermal fillers for rejuvenation has led to a rise in reports of associated complications. Although the majority of complications are mild and transient, serious and long-lasting complications have been observed. This article discusses the key complications including pigmentary changes, hypersensitivity reactions, infections, nodule formation, granulomatous reactions, vascular occlusion and migration of filler material. A thorough literature review was performed in addition to the combined extensive authors' (GP and FA) experience. Complications from fillers are increasingly being recognized and highlighted in the literature partly reflecting the growth in the market. This article provides a comprehensive overview of the filler complications with mechanisms of prevention and treatment per complication. A thorough understanding of the preventative and management strategies for the associated dermal filler complications will help the physician to prepare the patient well, and deal with complications that may arise effectively.

show abstract

Section: Nodule Formation and Granulomatous Reactionsmentioning

confidence: 99%

Dermal fillers: pathophysiology, prevention and treatment of complications

Chiang

Pierone

Al‐Niaimi

2016

Acad Dermatol Venereol

130

141

View full text Add to dashboard Cite

show abstract

“…Delayed reactions to hyaluronic acid dermal fillers are a recognised complication 6. Case series suggest presentations that include indurated papules or nodules with or without redness and tenderness, weeks to months after injection of fillers 7–9.…”

Section: Discussionmentioning

confidence: 99%

“…Case series suggest presentations that include indurated papules or nodules with or without redness and tenderness, weeks to months after injection of fillers 7–9. The pathogenesis was unclear in the above reports, however, was attributed to an immune response, likely delayed type IV hypersensitivity reaction to the fillers 6–8. Chronic inflammation around the dermal filler has also been recognised, potentially occurring secondary to bacterial infiltration 9…”

Section: Discussionmentioning

confidence: 99%

Cetuximab associated dermal filler reaction

Pathmanathan¹,

Dzienis

2019

BMJ Case Rep

View full text Add to dashboard Cite

A 52-year-old male patient with hyaluronic acid-based dermal fillers injected in his cheeks was diagnosed with glossotonsillary malignancy, and managed with concurrent cetuximab (epidermal growth factor receptor inhibitor) and radiation therapy. He developed significant inflammation around the dermal filler sites after first cycle of cetuximab which improved with dissolution of the dermal fillers with hyaluronidase. This suggests that cetuximab can lead to inflammation around the dermal filler sites, which can be treated with dissolution of the filler.

show abstract

“…A recent report documents delayed-onset nodules in 23 of 2,342 (0.5%) patients treated with Vycross over 68 months, with a median time to onset of 4 months (range, 1–13 months). 15 Following the results of this preliminary report, a larger comparative study has been initiated to clarify the nature of the inflammatory reactions observed.…”

Section: Discussionmentioning

confidence: 99%